ProQR Therapeutics N.V. PRQR
Set alert
As of Nov 3, 12:08 PM ET
- YTD
- -33.91%
- 1 year
- -48.46%
- Open
- 1.34
- Prev close
- 1.32
- Mkt cap
- 189.10M
- Vol
- 457.42K
- Avg vol
- 856.95K
- EPS
- -0.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.34
- High
- 1.39
- Forward P/E
- -5.68
- Beta
- 0.25
- Short ratio
- 0.31
- Inst. own
- 24.96%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.44
- 200-d avg
- 2.32
- 1y target
- 8.00
News
-
6 days ago benzinga.com
ProQR Therapeutics To Present Data On Its AX-0810, AX-0811 At The Liver Meeting 2026, Nature Conferences RNA
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing…
6 days ago globenewswire.com
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
2 weeks ago defenseworld.net
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to Analysts
ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the stock, Marketbeat…
1 month ago marketbeat.com
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
ProQR Therapeutics NASDAQ: PRQR said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid…
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.
1 month ago seekingalpha.com
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript
1 month ago globenewswire.com
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
Appointments support ProQR's strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified…
1 month ago globenewswire.com
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
2 months ago globenewswire.com
ProQR to Participate in Upcoming Investor Conferences in September 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
2 months ago seekingalpha.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts
I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company's AX-0810 achieved 8-fold serum bile acid…
2 months ago benzinga.com
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
-
2 months ago benzinga.com
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8
B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.
-
2 months ago benzinga.com
ProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of…
2 months ago globenewswire.com
ProQR Announces Second Quarter 2026 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
2 months ago defenseworld.net
Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)
ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
3 months ago defenseworld.net
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of “Moderate Buy” from Analysts
ProQR Therapeutics N.V. (NASDAQ: PRQR - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat.com reports. One…
4 months ago seekingalpha.com
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis
ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data.…
-
4 months ago benzinga.com
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6
Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.
4 months ago benzinga.com
ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche Bank, Baird, Stephens & Co.
-
4 months ago benzinga.com
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.
4 months ago benzinga.com
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success
ProQR reported positive AX-0810 Phase 1 data and raised $50 million, with Eli Lilly joining a concurrent share purchase.
-
4 months ago benzinga.com
ProQR Therapeutics Prices Registered Direct Offering Of 27,624,310 Shares At $1.81 Per Share For Total Gross Proceeds Of ~$50M; Also Enters Private Placement With Lilly For ~5.1M Shares At Same Offer Price
ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing…
4 months ago globenewswire.com
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives…
-
4 months ago benzinga.com
ProQR Therapeutics Announces Data From Its Ongoing Phase 1 Clinical Study Of AX-0810 Investigational Axiomer RNA Editing Oligonucleotide; Sees Target Engagement On All Key Biomarkers
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated…
4 months ago globenewswire.com
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated…
-
5 months ago benzinga.com
ProQR Therapeutics Q1 EPS $(0.15), Inline, Sales $2.381M Miss $5.530M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.10) per share from the same…
5 months ago globenewswire.com
ProQR Announces First Quarter 2026 Operating and Financial Results
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422…
5 months ago globenewswire.com
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
6 months ago zacks.com
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 months ago globenewswire.com
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
6 months ago globenewswire.com
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative…
-
6 months ago benzinga.com
ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
7 months ago benzinga.com
ProQR Therapeutics Q4 EPS $(0.09) Misses $(0.08) Estimate, Sales $5.458M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 10 percent increase over losses of…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
12 months ago benzinga.com
ProQR Therapeutics Q3 EPS $(0.10), Inline, Sales $2.882M Miss $8.550M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the…
-
12 months ago benzinga.com
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
ProQR Therapeutics Gets European Medicines Agency's Committee's Authorization For Clinical Trial Application For Phase 1 Trial Of AX-0810 To Treat Clerosing Cholangitis, Biliary Atresia
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate, Sales $4.327M Miss $4.408M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of…
-
1 year ago benzinga.com
ProQR Therapeutics Q2 EPS $(0.12) Misses $(0.09) Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of…
-
1 year ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target
Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Overweight and maintains $8 price target.
-
1 year ago benzinga.com
JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target
JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Market Outperform and maintains $8 price target.
-
1 year ago benzinga.com
Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9
Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and lowers the price target from $15 to $9.
-
1 year ago benzinga.com
Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Outperform rating and announces Price Target of $5.
-
1 year ago benzinga.com
ProQR Therapeutics Appoints Dennis Hom As CFO
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies…
-
1 year ago benzinga.com
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12
HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $10 to $12.